Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$51.99
$51.95
$14.95
$52.00
$3.71B1.221.68 million shs113 shs
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$25.59
$25.59
$9.90
$25.61
$2.21B0.191.29 million shs600 shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$6.16
+3.4%
$6.22
$5.51
$12.65
$1.83B0.513.16 million shs3.12 million shs
Insmed, Inc. stock logo
INSM
Insmed
$98.50
+0.3%
$80.30
$60.40
$106.83
$18.64B0.92.31 million shs1.76 million shs
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$42.97
$42.83
$32.67
$45.76
$1.62B0.5645,199 shsN/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00%0.00%0.00%0.00%0.00%
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
+1.88%+5.12%-3.41%-25.63%-39.59%
Insmed, Inc. stock logo
INSM
Insmed
+0.64%-6.30%+37.05%+33.97%+52.31%
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/AN/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
3.7167 of 5 stars
3.41.00.04.30.60.01.9
Insmed, Inc. stock logo
INSM
Insmed
4.1523 of 5 stars
2.54.00.04.33.41.70.6
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00
N/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
0.00
N/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.70
Moderate Buy$16.22163.56% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$106.808.43% Upside
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TARO, INSM, DCPH, FOLD, and CCXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $109.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $120.00
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$100.00 ➝ $115.00
5/2/2025
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $22.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$32.22M115.14N/AN/A$4.09 per share12.71
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
$174.91M12.65N/AN/A$4.38 per share5.84
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$528.29M3.59N/AN/A$0.65 per share9.47
Insmed, Inc. stock logo
INSM
Insmed
$363.71M51.38N/AN/A$1.60 per share61.56
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$629.18M2.57$2.38 per share18.03$47.70 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$56.11M-$0.09N/A14.31N/A-5.41%4.67%1.05%8/14/2025 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
$53.87M$1.4429.84N/A8.56%3.75%3.09%N/A

Latest TARO, INSM, DCPH, FOLD, and CCXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/A
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.02
4.54
4.47
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
N/A
4.19
3.94
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.02
3.34
2.47
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
N/A
3.61
3.04
CompanyEmployeesShares OutstandingFree FloatOptionable
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
17871.36 million65.43 millionOptionable
Deciphera Pharmaceuticals, Inc. stock logo
DCPH
Deciphera Pharmaceuticals
30086.48 million82.44 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480307.93 million301.16 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
Taro Pharmaceutical Industries Ltd. stock logo
TARO
Taro Pharmaceutical Industries
1,55437.59 million32.40 millionOptionable

Recent News About These Companies

FDA approves first generics of anticoagulant Xarelto
Taro to acquire 100% stake in Antibe Therapeutics
Sun Pharma unit poised to buy Canadian biotech Antibe

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ChemoCentryx stock logo

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Deciphera Pharmaceuticals stock logo

Deciphera Pharmaceuticals NASDAQ:DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

$6.16 +0.21 (+3.45%)
Closing price 03:39 PM Eastern
Extended Trading
$6.08 -0.08 (-1.22%)
As of 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Insmed stock logo

Insmed NASDAQ:INSM

$98.50 +0.26 (+0.26%)
Closing price 03:07 PM Eastern
Extended Trading
$98.50 0.00 (0.00%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Taro Pharmaceutical Industries stock logo

Taro Pharmaceutical Industries NYSE:TARO

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.